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Available online 26 May 2016Genome-wide analysis of DNAmethylation has now become a relatively inexpensive technique thanks to array-
based methylation proﬁling technologies. The recently developed Illumina Inﬁnium MethylationEPIC BeadChip
interrogates methylation at over 850,000 sites across the human genome, covering 99% of RefSeq genes. This
array supersedes the widely used Inﬁnium HumanMethylation450 BeadChip, which has permitted insights
into the relationship between DNA methylation and a wide range of conditions and traits. Previous research
has identiﬁed issues with certain probes on both the HumanMethylation450 BeadChip and its predecessor, the
Inﬁnium HumanMethylation27 BeadChip, which were predicted to affect array performance. These issues con-
cerned probe-binding speciﬁcity and the presence of polymorphisms at target sites. Using in silico methods,
we have identiﬁed probes on the InﬁniumMethylationEPIC BeadChip that are predicted to (i) measure methyl-
ation at polymorphic sites and (ii) hybridise to multiple genomic regions. We intend these resources to be used
for quality control procedures when analysing data derived from this platform.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Keywords:
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DNA methylation is an epigenetic mark typically occurring at cyto-
sine-guanine dinucleotides (CpGs). Changes in DNA methylation are
observed in normal development, in response to environmental stimuli,
and in certain disease states [1]. DNAmethylation is linked to transcrip-
tional activity, rendering it a key regulatory motif [2]. Recent years have
seen the development of high-throughput DNA methylation proﬁling
techniques including whole-genome bisulphite sequencing (WGBS),
methylated DNA immunoprecipitation (meDIP) and microarray-based
technologies [3]. The InﬁniumHumanMethylation450 BeadChip, devel-
oped by Illumina, has offered an attractive array-based option to re-
searchers, as it interrogates methylation at over 485,000 sites across
the genome at single-base resolution at a relatively low cost (Bibikova
et al., 2011 [4]). However, issues with probe-binding speciﬁcity and
polymorphic targets have been identiﬁed which may compromise
data integrity if not adequately addressed (Chen et al., 2013 [5]).
The Inﬁnium HumanMethylation450 BeadChip has recently been
superseded by the InﬁniumMethylationEPIC BeadChip. This array inter-
rogates DNA methylation at over 850,000 sites, including N90% of the
HumanMethylation450 array's targets. This substantial increase in
coverage, coupled with a continuing trend for interest in the role of
DNA methylation, is likely to result in wide-spread use of this array.the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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understood. In order to generate a resource that will be of use to re-
searchers using the MethylationEPIC BeadChip we have identiﬁed
probes that may perform sub-optimally. This work, therefore, repre-
sents an update of Chen et al.'s [5] previous characterisation of the
Inﬁnium HumanMethylation450 BeadChip.
Like its predecessor, the MethylationEPIC BeadChip uses two types
of probe chemistry (Type I and Type II) to interrogate methylation.
The differences between the two chemistries and the situations in
which they are used have been described fully in previous publications
[6]. Brieﬂy, Type I assays use separate probes for unmethylated and
methylated target sites while Type II assays use a single probe. Both
assay types differentiate methylation state via single base extension of
a ﬂuorescent-labelled nucleotide.
Taking the differences between Type I and Type II assays into consid-
eration, we have performed in silico analyses to identify probes on the
Inﬁnium MethylationEPIC BeadChip that are predicted to hybridise to
multiple genomic regions, as well as probes where signal may be affect-
ed by polymorphisms at the target site, which could alter probe binding.
Both of these factors should be taken into account when performing
quality control of data produced using this technology.
3. Methods
3.1. Identiﬁcation of probes with a polymorphic target
Probes potentially affected by polymorphisms at the target site were
identiﬁed following methods described previously [5].
The signal-generating process of single-base extension requires end-
nucleotide matching for both Type I and Type II probes. Therefore, we
limited our query to target CpGs and sites of single-base extension, as
polymorphisms at these sites are most likely to generate spurious
signals.
Using information from the Inﬁnium MethylationEPIC BeadChip
manifest ﬁle (MethylationEPIC_v-1-0_B1.csv; date of download: 8 Feb-
ruary 2016), we generated a list of genomic coordinates (hg19,
GRCh37) of the target cytosine base (C) and guanine base (G) for all
probes on the array. For Inﬁnium Type I probes we also included the
base before the target CpG, as this is the site of single base extension
for these probes.We cross-referenced these coordinates to those of var-
iants listed by the 1000 Genomes Project (phase 3) [7] to generate a list
of probes affected by polymorphisms at the target CpG and/or site of
single-base extension.
3.2. Identiﬁcation of probes with non-speciﬁc hybridisation potential
Probes with the potential to cross-hybridise were identiﬁed follow-
ing methods described previously [5].
3.2.1. Generation of probe sequences for in silico analyses
Many Inﬁnium Type II probe sequences contain an “R” nucleotide
representing either an adenine (A) or guanine (G) base, depending on
whether the underlying target cytosine is methylated or unmethylated.
All possible combinations of Type II probe sequences were generated,
and combined with a list of the Type I probe sequences.
3.2.2. Generation of genomic comparison sequences for in silico analyses
The GRCh37 release of the human genome sequence was
downloaded from the University of California, Santa Cruz (UCSC)
Genome Browser website (https://genome.ucsc.edu/) as a reference,
excluding alternative assemblies (e.g. chr17_ctg5_hap1) to avoid
duplicated results (date of download: 11 January 2016). From this, we
generated four modiﬁed reference genome sequences. A bisulphite-
converted methylated forward genome sequence was generated in
silico by converting all non-CpG cytosine bases to thymine (T) bases in
the reference sequence. The same process was performed for thereverse complement of the reference sequence to generate a
bisulphite-converted methylated reverse sequence of the human
genome. Bisulphite-converted unmethylated forward and reverse
sequences were generated by converting all C bases to T in the forward
reference sequence and its reverse complement.
Using the BLAST-like alignment tool (BLAT) [8], we aligned the
probe sequences described above to the four modiﬁed reference ge-
nome sequences, as well as their reverse complements. The BLAT pa-
rameters used were: stepSize = 5, minScore = 0, minIdentity = 0 and
repMatch = 1,000,000,000. Probes were deﬁned as being at high-risk
of non-speciﬁc binding if there was a gap-free match of 47 or more
nucleotides, which had to include the end base of the query sequence,
at an off-target locus.
4. Results
4.1. Inﬁnium MethylationEPIC BeadChip probes with polymorphic targets
Coordinates for 866,836 probes were obtained from the Inﬁnium
MethylationEPIC BeadChip manifest downloaded on 8th February
2016. Excluding control probes, the manifest ﬁle contained 142,262
Type I probes (426,786 potential signal-affecting positions), and
724,574 Type II probes (1,449,148 potential signal-affecting positions),
giving a total of 1,875,934 sites which were interrogated for genetic
variation.
We identiﬁed 340,327 sites with either single nucleotide polymor-
phisms (SNPs), insertions or deletions (indels), or structural variation.
These sites were targeted by 297,744 unique probes: 34% of the
total probe content of the Inﬁnium MethylationEPIC BeadChip. Of
these, 23,399 probes (2.7%) targeted polymorphic sites with a minor
allele frequency (MAF) of ≥5% in at least one population studied.
A table of probes affected by polymorphisms, with minor allele
frequencies corresponding to African, admixed American, European,
South Asian, and East Asian populations (AFR, AMR, EUR, SAS, EAS;
respectively) is available in the supplementary information of this
paper (Supplementary Table 1).
4.2. Inﬁnium MethylationEPIC BeadChip probes with cross-hybridisation
potential
A total of 1,752,932 potential probe sequences, each 50 bases in
length, were aligned to in silico bisulphite-converted forward and re-
verse methylated and unmethylated reference genomes, and their cor-
responding complementary strands in BLAT (i.e. eight single-stranded
genomes in total). We identiﬁed 44,210 probes (11,772 Type I probes
and 32,438 Type II probes) with ≥47 nucleotide off-target matches
including the end base, which were deﬁned as potentially cross-
hybridising. A list of these probes is available in the supplementary in-
formation of this paper (Supplementary Tables 2–3).
Consistent with ﬁndings on the Inﬁnium HumanMethylation450
BeadChip [5], a larger proportion of non-CpG-targeting probes (Probe
ID preﬁx = “ch”) were identiﬁed as potentially cross-hybridising com-
pared to CpG-targeting probes (Probe ID preﬁx = “cg”). Of 863,904
CpG-targeting probes present on the array, 42,558 (4.9% of total CpG-
targeting probes) were identiﬁed as potentially cross-hybridising
(Supplementary Table 2). In contrast, of 2932 non-CpG targeting
probes, we found only 1280 to bind speciﬁcally to their targets while
the remaining 1652 were potentially cross-hybridising (56% of total
non-CpG targeting probes; Supplementary Table 3), based on the infor-
mation provided in the Illumina manifest.
5. Discussion
In order to identify probes that might compromise the performance
of the Illumina InﬁniumMethylationEPIC BeadChip, we have generated
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morphisms at the target site.
Our in silico analyses identiﬁed 44,210 probes (5.1% total probe con-
tent) with potential off-target binding sites and 23,399 probes (2.7%
total probe content) whose target site contains a polymorphism with
a MAF ≥ 0.05 in at least one population studied, which may lead to
artefactual signal due to impaired probe-binding. We recommend that
users take these probes into consideration when analysing data on
this platform, applying the appropriate ﬁltering criteria in a popula-
tion-speciﬁc manner, where possible. We recognise that there may be
some situationswhere retaining probesmapping to polymorphic target
sites will be desirable. For example, a difference in methylation due to a
SNP that creates or destroys a CpG at a target site may be informative if
it confers a change in disease risk.
Chen et al. (2013) [5] demonstrated that autosomal probes deﬁned
as potentially cross-hybridising according to their criterion of an off-tar-
get match of 47/50 bases, including the end nucleotide, showed an en-
richment for off-target binding sites on the sex chromosomes. Failure
to exclude these probes could, therefore, result in the spurious conclu-
sion that these loci are differentially methylated between males and fe-
males. Following their methods, we have identiﬁed probes on the
Inﬁnium MethylationEPIC BeadChip with the potential to hybridise to
multiple genomic regions, thus generating off-target signal. We suggest
the exclusion of these probes prior to data analysis. Although the exclu-
sion of potentially cross-hybridisingprobes deﬁned using thismethod is
likely to result in an improvement in the validity of the results obtained
from the array, it is likely that the actual extent of off-target bindingwill
vary by locus. Factors such as local sequence composition, including the
presence of polymorphismsunderlying the probe sequence, are likely to
play a role in determining the likelihood of cross-hybridisation. It is,
therefore, recommended that any results of interest that may have
been generateddue to cross-hybridisation are checked using an alterna-
tive technique, such as pyrosequencing of bisulphite-converted DNA.
In summary, we have produced lists of probes on the new Illumina
Inﬁnium MethylationEPIC BeadChip that measure methylation at sites
affected by polymorphisms and/or have thepotential to cross-hybridise.
Based on the wide-spread use of the HumanMethylation450 BeadChip,
we predict that the Illumina Inﬁnium MethylationEPIC BeadChip will
play a central role in epigenome-wide association studies (EWAS)
over the next few years. As such, it is essential that factors affecting
the performance of the array, such as probe speciﬁcity and sequence
polymorphisms, which we have demonstrated to potentially affect a
substantial proportion of probes, are taken into consideration. We rec-
ommend that the resources supplied with this paper be used inconjunction with additional standard quality control measures, such
as excluding probes with low signal-to-background ratios, omission of
samples with a high proportion of such probes, and appropriate data
normalisation strategies (for review see Wilhelm-Benartzi et al., 2013
[9]), in order to maximise the likelihood of producing meaningful
results.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.gdata.2016.05.012.
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